Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$4.69
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.69
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$3.86 - $9.58
Previous CloseN/A
Volume344.54K
Average Volume (3M)756.56K
Market Cap
$393.81M
Enterprise Value$383.03
Total Cash (Recent Filing)$49.79M
Total Debt (Recent Filing)$164.90M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding65,854,750
10 Day Avg. Volume763,153
30 Day Avg. Volume756,558
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.50Price Target Upside209.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$330.45M
Bulls Say, Bears Say
Bulls Say
Revenue & Gross MarginsSustained multi-year revenue expansion alongside ~65% gross margins indicates durable product economics and pricing power for Jeuveau. Strong top-line growth plus high gross margins create room to absorb SG&A, support operating leverage, and provide a credible path to sustained profitability as scale increases.
Commercial Reach & LoyaltyA large and growing rewards ecosystem with high reorder rates and rising account penetration strengthens recurring demand and lowers long-term customer acquisition costs. Embedding AI in its data platform can improve field productivity and targeted engagement, supporting durable cross-sell and monetization of future product launches.
Portfolio Diversification (Profhilo Deal)The capital-efficient Profhilo U.S. distribution agreement diversifies Evolus beyond neurotoxins into skin-quality injectables without large upfront cash commitments. If approved, this broadens the addressable market, leverages existing commercial channels, and strengthens long-term competitive position with limited near-term capex.
Bears Say
Balance Sheet LeverageNegative equity and elevated debt materially weaken financial flexibility and increase refinancing and covenant risk. A leveraged balance sheet limits ability to fund launches, pursue M&A, or absorb shocks, and raises the probability of dilutive or costly external financing if operating cash generation does not improve.
Weak Cash GenerationPersistent negative operating and free cash flow forces reliance on external capital and reduces optionality to invest in marketing, inventory, or new product commercialization. This increases execution risk for launches and international expansion and heightens vulnerability if capital markets tighten or credit costs rise.
Competitive & Product Pipeline RiskEvolisse remains a small contributor and the filler market is flat, while established competitors and new neurotoxin entrants raise required spend to defend/grow share. Sculp's U.S. approval is pending, so meaningful mid-face filler exposure hinges on future regulatory success and effective commercialization.
Evolus News
EOLS FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was $3.86 and its highest was $9.58 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is $393.81M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 9 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on May 04, 2026. The company reported -$0.046 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.067.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 65,854,750 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -$0.046 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went up 14.158%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (209.17% Upside)
$14.50 (209.17% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive picture: revenue growth (Q1 +7%), healthy margins (adjusted gross margin 68%), expanding commercial footprint and loyalty (Rewards members +27% YoY), and a return to positive adjusted EBITDA ($0.6M) alongside reiterated full-year guidance and planned product launches (Esteem in Europe, Sculp FDA in Q4). Key risks include timing/seasonality comparatives, a newly announced 15% South Korea tariff on certain products, a still-small contribution from Evolisse amid a soft filler market, and continued competitive entrants. On balance, the operational improvements, profitability momentum, and clear pipeline/launch cadence outweigh the cited headwinds.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(209.17% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.13% Insiders
7.96% Mutual Funds
1.57% Other Institutional Investors
75.37% Public Companies and
Individual Investors